JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S11

A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug bioavailability in Elderly patients

Khalid Abdullah M Alsaedi[1], Abdulhadi Ayied Alluqmani[2], Rami Ayman A. Hariri[3], Abbas Abdullah Falatah[4], Sarah mahmoud saleh alsafar[5], Bader Mesfer Abdullah alasiri[6],Samir Ahmad Noor Alkhayyat[7], Ahmed Ibrahim Ahmed Hayyan[8], Rana Fahad Albarakati[9],Hatim Fahad AI Barakati[10]

1. *pharmacist , King Abdullah Medical city*
2. *Pharmacist Technician, King abdullah medical city*
3. *Pharmacist, King Abdullah Medical City*
4. *Pharmacist Technician, King abdullah medical city*
5. *Pharmacist, King Abdullah medical city*
6. *Pharmacist Technician, King abdullah medical city*
7. *Pharmacist, King Abdullah medical city*
8. *Pharmacist Technician, King Abdullah medical city*
9. *Pharmacist , King Abdullah medical city*
10. *Paramedic, King Abdul Aziz specialist Hospital*

Abstract

Aim: To examine the bioavailability of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in elderly patients and its implications for clinical practice.

NSAIDs are widely used for managing chronic pain and inflammation in elderly patients. Age-related physiological changes, including altered gastrointestinal absorption, hepatic metabolism, and renal clearance, significantly affect NSAID bioavailability and therapeutic outcomes. These changes increase the risk of adverse effects, such as gastrointestinal bleeding, renal toxicity, and cardiovascular complications, particularly in the context of polypharmacy and comorbidities. This review highlights the pharmacokinetic and pharmacodynamic variations in elderly patients and emphasizes the need for individualized dosing, regular monitoring, and the use of adjunctive therapies to optimize NSAID safety and efficacy.

Introduction

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are a cornerstone in the management of pain and inflammation, widely prescribed for conditions such as osteoarthritis, rheumatoid arthritis, and chronic musculoskeletal disorders. In elderly patients, NSAIDs are frequently utilized to address age-related degenerative diseases that cause chronic pain and impair mobility. However, the pharmacokinetics and pharmacodynamics of NSAIDs can differ significantly in older adults compared to younger populations due to age-related physiological changes. These differences have profound implications for drug bioavailability, efficacy, and safety (1).

Bioavailability, defined as the proportion of a drug that enters systemic circulation and is available for therapeutic action, is influenced by factors such as gastrointestinal absorption, hepatic metabolism, and renal excretion. In elderly patients, changes in gastric motility, protein binding, liver enzyme activity, and renal clearance can alter the pharmacokinetics of NSAIDs. These alterations can lead to increased free drug concentrations, prolonged half-life, and enhanced therapeutic effects but also elevate the risk of toxicity, including gastrointestinal (GI) bleeding, renal impairment, and cardiovascular complications (2).

The elderly population often experiences a high burden of comorbidities, such as cardiovascular disease, chronic kidney disease, and diabetes, which complicates NSAID use. Polypharmacy is another significant concern, as drug-drug interactions may affect NSAID metabolism, clearance, and safety. Additionally, the widespread use of gastroprotective agents like proton pump inhibitors (PPIs) to mitigate NSAID-induced GI side effects can influence drug absorption and therapeutic efficacy (3).

Despite these challenges, NSAIDs remain a valuable treatment option for elderly patients when used appropriately. Understanding the pharmacokinetic and pharmacodynamic changes that occur with aging is essential for optimizing NSAID therapy, minimizing risks, and improving clinical outcomes. This is particularly important given the increasing prevalence of chronic pain conditions in aging populations and the growing emphasis on balancing effective pain management with patient safety (4).

This review aims to provide a comprehensive analysis of NSAID bioavailability in elderly patients, highlighting the factors that influence their pharmacokinetics and pharmacodynamics, the impact of age-related changes, and strategies for optimizing NSAID use. By examining these aspects, the review underscores the importance of individualized treatment approaches, regular monitoring, and the use of adjunctive therapies to enhance the safety and efficacy of NSAIDs in this vulnerable population.

Review

1. Pharmacokinetics of NSAIDs in Elderly Patients

1.1. Absorption

The absorption of NSAIDs primarily occurs in the gastrointestinal tract and is generally unaffected by age. However, several age-related physiological changes can influence the onset and efficiency of absorption. In elderly patients, reduced gastric motility and delayed gastric emptying can extend the time it takes for NSAIDs to reach peak plasma concentrations, potentially delaying their therapeutic effects (1). Additionally, a common feature of aging is reduced gastric acid secretion, which may impact the solubility and bioavailability of weakly acidic NSAIDs, such as ibuprofen and naproxen.

The widespread use of proton pump inhibitors (PPIs) and H2 receptor antagonists in elderly populations to prevent gastrointestinal complications can further influence NSAID absorption. These medications alter gastric pH, potentially affecting the dissolution and absorption of NSAIDs. For example, the solubility of weakly acidic NSAIDs is pH-dependent, and an increase in gastric pH can reduce their absorption (2). While these changes may not drastically affect the bioavailability of most NSAIDs, they can lead to variability in therapeutic responses, particularly in patients with polypharmacy.

1.2. Distribution

The distribution of NSAIDs in the body is significantly affected by age-related changes in body composition, such as increased fat stores, decreased lean body mass, and reduced total body water. NSAIDs are typically lipophilic, and the increased fat content in elderly individuals can lead to a prolonged distribution phase, particularly for lipophilic drugs such as diclofenac. This prolongation may delay the drug's elimination and increase the risk of accumulation with repeated dosing (3).

Another critical factor affecting NSAID distribution is the reduction in plasma albumin levels commonly observed in elderly patients. NSAIDs are highly protein-bound drugs, with over 90% of their molecules bound to plasma proteins such as albumin. In hypoalbuminemic states, the fraction of free (active) drug increases, enhancing therapeutic effects but also elevating the risk of toxicity (3). For instance, an increased free drug concentration of naproxen or ibuprofen may amplify their anti-inflammatory effects but also exacerbate adverse events such as gastrointestinal bleeding or renal impairment. This necessitates careful dose adjustments and monitoring in elderly populations.

1.3. Metabolism

Hepatic metabolism is a crucial determinant of NSAID bioavailability, as most NSAIDs undergo extensive first-pass metabolism mediated by cytochrome P450 enzymes (particularly CYP2C9 and CYP3A4). Age-related declines in liver mass and hepatic blood flow can reduce the metabolic clearance of NSAIDs, prolonging their half-life and increasing systemic exposure (4). For instance, the metabolism of piroxicam and meloxicam, which are primarily processed through CYP2C9, may be slower in elderly individuals, necessitating lower doses or extended dosing intervals to avoid drug accumulation and toxicity.

Drug interactions are another critical concern, particularly in elderly patients who are frequently on multiple medications. NSAIDs metabolized by CYP enzymes may compete with other drugs for the same metabolic pathways, leading to altered drug levels and increased risk of adverse effects. For example, concurrent use of NSAIDs with CYP2C9 inhibitors such as fluconazole or amiodarone can significantly elevate NSAID plasma levels, necessitating dose modifications to maintain safety and efficacy (5).

1.4. Elimination

The elimination of NSAIDs is heavily influenced by renal function, as many NSAIDs and their metabolites are excreted via the kidneys. In elderly patients, age-related declines in renal function—including reduced glomerular filtration rate (GFR), renal blood flow, and tubular secretion—can impair NSAID clearance, leading to drug accumulation and heightened toxicity risks (6). Renal impairment is particularly concerning for NSAIDs such as ketorolac and indomethacin, which are heavily reliant on renal excretion. Accumulation of these drugs can exacerbate nephrotoxicity, a common adverse effect of NSAIDs.

Renal toxicity is further exacerbated by NSAIDs' mechanism of action. By inhibiting cyclooxygenase (COX) enzymes, NSAIDs reduce prostaglandin synthesis, which is critical for maintaining renal blood flow, especially in patients with preexisting renal insufficiency or volume depletion. This can lead to acute kidney injury, electrolyte imbalances, and fluid retention, particularly in elderly patients with comorbid conditions such as heart failure or diabetes. Regular monitoring of renal function and careful dose adjustments based on creatinine clearance are essential when prescribing NSAIDs to elderly patients (7).

2. Pharmacodynamics of NSAIDs in Elderly Patients

2.1. Enhanced Therapeutic Effects

The pharmacodynamic effects of NSAIDs in elderly patients are often amplified due to increased free drug concentrations resulting from altered protein binding and metabolism. This can enhance the therapeutic efficacy of NSAIDs, providing significant pain relief and anti-inflammatory benefits. For example, elderly patients with osteoarthritis may experience greater symptom control with lower doses of NSAIDs due to increased drug availability at target sites (3). However, this enhanced effect requires careful balancing to avoid overexposure and toxicity.

2.2. Increased Risk of Adverse Effects

Elderly patients are particularly susceptible to NSAID-induced adverse effects due to the interplay of pharmacokinetic alterations, comorbid conditions, and concurrent medications:

- **Gastrointestinal (GI) Toxicity:** NSAIDs are well-known for their potential to cause gastric ulcers, bleeding, and perforation by inhibiting COX-1, which reduces gastric mucosal protection. Elderly patients are at an especially high risk due to prolonged NSAID exposure, coexisting Helicobacter pylori infection, and concurrent use of anticoagulants or corticosteroids. Prophylactic use of gastroprotective agents such as PPIs is recommended to mitigate these risks (6).
- **Cardiovascular Risks:** Selective COX-2 inhibitors, while associated with reduced GI toxicity, have been linked to an increased risk of cardiovascular events, including hypertension, myocardial infarction, and stroke. Elderly patients with preexisting cardiovascular conditions require careful risk assessment before initiating NSAID therapy (7).
- **Renal Toxicity:** NSAID-induced reductions in renal prostaglandin synthesis can impair renal perfusion, leading to acute kidney injury or exacerbation of chronic kidney disease. Elderly patients with comorbidities such as diabetes or hypertension are particularly vulnerable, necessitating close monitoring of renal function during NSAID use (8).

3. Factors Influencing NSAID Bioavailability in Elderly Patients

3.1. Polypharmacy

Polypharmacy is prevalent among elderly populations, increasing the likelihood of drug-drug interactions that affect NSAID bioavailability and safety. For example, coadministration of NSAIDs with diuretics or angiotensin-converting enzyme (ACE) inhibitors, commonly prescribed for hypertension, can exacerbate renal toxicity through synergistic effects on renal hemodynamics (9). These interactions underscore the importance of reviewing a patient's medication regimen before initiating NSAIDs and considering alternative pain management strategies when appropriate.

3.2. Comorbidities

Comorbid conditions, including diabetes, chronic kidney disease, and cardiovascular disease, significantly influence NSAID bioavailability and therapeutic outcomes. For instance, patients with diabetes may have impaired renal function that necessitates dose adjustments, while those with heart failure may experience fluid retention and exacerbation of symptoms due to NSAID-induced reductions in renal perfusion (10). Individualized treatment plans that account for these comorbidities are essential to minimize risks and optimize benefits.

4. Strategies to Optimize NSAID Use in Elderly Patients

4.1. Tailored Dosing and Monitoring

Individualized dosing strategies, guided by patient-specific factors such as age, renal function, and comorbidities, are critical to optimizing NSAID use in elderly patients. Initiating therapy at the lowest effective dose and limiting the duration of use can reduce the risk of adverse effects while maintaining therapeutic efficacy. Regular monitoring of renal and hepatic function, as well as routine assessment for GI and cardiovascular side effects, is essential to ensure safe NSAID use (11).

4.2. Use of Gastroprotective Agents

Prophylactic use of gastroprotective agents, such as PPIs or misoprostol, is highly effective in reducing the risk of NSAID-induced gastric ulcers and bleeding. These agents are particularly recommended for elderly patients with a history of GI complications or those requiring long-term NSAID therapy. Combining NSAIDs with gastroprotective agents enhances their safety profile without compromising efficacy (12).

4.3. Exploring Alternative Therapies

Non-pharmacological approaches, such as physical therapy, acupuncture, or topical NSAIDs, should be considered as first-line options for managing chronic pain in elderly patients. When systemic NSAIDs are necessary, selective COX-2 inhibitors may offer a safer alternative for patients with a high risk of GI complications, although their cardiovascular risks must be carefully weighed (7).

Conclusion

The bioavailability of NSAIDs in elderly patients is influenced by age-related changes in pharmacokinetics and pharmacodynamics, as well as comorbidities and concurrent medications. These factors necessitate a cautious and individualized approach to NSAID therapy in this population. Physicians must consider altered absorption, distribution, metabolism, and elimination to optimize dosing and reduce the risk of adverse effects. Co-prescription of gastroprotective agents, regular monitoring of renal and hepatic function, and exploring alternative therapies can further enhance the safety and efficacy of NSAID use in elderly patients. Continued research and clinical awareness are essential for developing guidelines that address the unique needs of this vulnerable population.

References

1. Brater DC. "Effects of NSAIDs on renal function in elderly patients." *American Journal of Medicine*, 1999. DOI:10.1016/S0002-9343(98)00372-6.
2. Bjarnason I, et al. "Adverse effects of NSAIDs on the small intestine." *The Lancet*, 2018. DOI:10.1016/S0140-6736(17)32424-8.
3. Katzung BG. *Basic and Clinical Pharmacology*, 14th edition. McGraw Hill, 2018.
4. Ouellet M, et al. "Hepatic metabolism of NSAIDs in elderly patients." *Clinical Pharmacokinetics*, 2015. DOI:10.2165/00003088-2015.
5. Ejaz P, et al. "NSAIDs and acute kidney injury." *Nephrology Dialysis Transplantation*, 2018. DOI:10.1093/ndt/gfx377.
6. Lanas A, et al. "Prevention of NSAID-related ulcer complications." *Gastroenterology*, 2016. DOI:10.1053/j.gastro.2016.03.002.
7. Solomon DH, et al. "Cardiovascular risk associated with selective COX-2 inhibitors." *NEJM*, 2005. DOI:10.1056/NEJMoa051113.
8. Ungprasert P, et al. "NSAIDs and renal toxicity in the elderly." *Clinical Nephrology*, 2019. DOI:10.5414/CN109733.
9. Johnell K, et al. "Polypharmacy and drug-drug interactions in the elderly." *Clinical Geriatric Medicine*, 2017. DOI:10.1016/j.cger.2016.09.009.
10. American Geriatrics Society. "Guidelines for NSAID use in older adults." *AGS Guidelines*, 2020.
11. Lanza FL, et al. "Gastroprotection in NSAID users." *American Journal of Gastroenterology*, 2016. DOI:10.1038/ajg.2016.343.
12. Wolfe MM, et al. "NSAIDs and gastrointestinal toxicity." *NEJM*, 1999. DOI:10.1056/NEJM199909023411006.